Hikma Pharmaceutical | HIK - Gross Profit On Sales


Hikma Pharmaceutical reported $362.5M in Gross Profit on Sales for its fiscal semester ending in June of 2025.





Gross Profit On Sales Change Date
Almirall EUR 429.87M 180.02M Dec/2025
argenx SE USD 1.18B 40.98M Mar/2026
AstraZeneca USD 12.61B 225M Mar/2026
Autolus Therapeutics Ltd USD 1.65M 2.69M Mar/2026
Bayer EUR 6.94B 1.58B Dec/2025
Fresenius EUR 1.51B 214M Dec/2025
Genmab DKK 977M 13M Dec/2025
GlaxoSmithKline GBP 5.75B 429M Mar/2026
GRIFOLS EUR 686.84M 56.95M Dec/2025
Hikma Pharmaceutical USD 362.5M 329.5M Jun/2025
Lakefront Biotherapeutics EUR 1.68M 898.68M Mar/2026
Lonza CHF 1.29B 248M Jun/2025
Merck EUR 3.07B 104M Mar/2026
Orion EUR 254M 254.7M Mar/2026
Recordati EUR 472.65M 40.24M Dec/2025
Roche Holding CHF 22.09B 10.04B Dec/2025
Sanofi EUR 8.45B 1.31B Dec/2025
UCB EUR 3.19B 621M Dec/2025